BioSpace News Archive

Job Trends

BioSpace Movers and Shakers: April 19

Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.

April 18, 2019
·
5 min read
·
Alex Keown
Medtronic VenaSeal(TM) Closure System Demonstrates Durable and Consistent Outcomes at Five Years in Patients with Chronic Venous Disease

Medtronic plc announced five-year outcomes from the VeClose Extension Study.

April 18, 2019
·
3 min read
Polyphor presents new data at ECCMID from its lead antibiotic murepavadin and the new OMPTA POL7306

Murepavadin to be more potent than standard of care anti-Pseudomonas antibiotics against multidrug and colistin resistant Pseudomonas aeruginosa isolates

April 18, 2019
·
5 min read
Novotech CRO strengthens South Korean Clinical Capabilities partnering with 2 Major Hospitals

Ulsan University Hospital (UHH) and Seoul National University Hospital (SNUH), Hepatology Division have joined the Novotech CRO partnership program

April 18, 2019
·
2 min read
Medtronic Data Expands on Key Aortic Solutions for Challenging Anatomies

New EndoSuture Aneurysm Repair (ESAR) and Valiant Navion(TM) Data Presented at Charing Cross Demonstrate Safety and Efficacy in Patients with Complex Anatomies

April 18, 2019
·
5 min read
Deals

Recipharm publishes Annual Report 2018

The report summarises the business and highlights for 2018 and gives insights into the company’s strategy.

April 18, 2019
·
1 min read
Business

CENTOGENE Appoints AI Industry Leader Dr. Carsten Ullrich as Director of Artificial Intelligence

Research Fellow from German Research Center for Artificial Intelligence to lead team driving solutions for pharmaceutical partners

April 18, 2019
·
2 min read
Job Trends

Triple negative breast cancers can adopt reversible state that is resistant to chemotherapy

Study finds that resistant cells become vulnerable to MD Anderson-developed targeted therapy

April 18, 2019
·
5 min read
Deals

Exelixis to Release First Quarter 2019 Financial Results on Wednesday, May 1, 2019

Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT

April 18, 2019
·
2 min read
Genetown

Arrakis Therapeutics Nabs $75 Million to Create a New Class of rSM Oncology Drugs

The funding will allow Arrakis to realize its vision of creating a new class of medicines with RNA-targeted small molecules, or rSMs.

April 18, 2019
·
2 min read
·
Alex Keown